English | 繁體

Search in the results

UM

Browse/Search Results:  1-10 of 11 Help

Selected(0)Clear Items/Page:    Sort:
CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer Journal article
Wei-Bang Yu, Yu-Chi Chen,, Can-Yu Huang, Zi-Han Ye, Wei Shi, Hong Zhu, Jia-Jie Shi, Jun Chen, Jin-Jian Lu. CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer[J]. Frontiers of Medicine, 2022, 17(1), 105-118.
Authors:  Wei-Bang Yu;  Yu-Chi Chen,;  Can-Yu Huang;  Zi-Han Ye;  Wei Shi; et al.
Favorite | TC[WOS]:2 TC[Scopus]:2  IF:3.9/5.4 | Submit date：2023/01/30
Adcp  Anti-cd47 Antibody  Combination Strategy  Egfr  Osimertinib  
TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance Journal article
Jiang,Xiao ming, Xu,Yu lian, Yuan,Luo wei, Zhang,Le le, Huang,Mu yang, Ye,Zi han, Su,Min xia, Chen,Xiu ping, Zhu,Hong, Ye,Richard D., Lu,Jin jian. TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance[J]. Acta Pharmacologica Sinica, 2020, 42(3), 451-459.
Authors:  Jiang,Xiao ming;  Xu,Yu lian;  Yuan,Luo wei;  Zhang,Le le;  Huang,Mu yang; et al.
Favorite | TC[WOS]:40 TC[Scopus]:39  IF:6.9/7.6 | Submit date：2021/03/01
Egfr Mutant Non-small Cell Lung Cancer  Emt  Nf-κb  Osimertinib Resistance  Tgfβ2  
TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance Journal article
Jiang, XM, Xu, YL, Yuan, LW, Zhang, LL, Huang, MY, Ye, ZH, Su, MX, Chen, X. P., Zhu, H, Ye, R, Lu, J.. TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance[J]. Acta Pharmacologica Sinica, 2020, 451-459.
Authors:  Jiang, XM;  Xu, YL;  Yuan, LW;  Zhang, LL;  Huang, MY; et al.
Favorite |  | Submit date：2022/08/26
Egfr Mutant Non-small Cell Lung Cancer  Nf-κb  Tgfβ2  Epithelial-mesenchymal Transition  Osimertinib Resistance  
Increased expression of IRE1α associates with the resistant mechanism of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells Journal article
Zheng-hai Tang, Min-Xia Su, Xia Guo, Xiao-Ming Jiang, Lin Jia, Xiuping Chen, Jin-Jian Lu. Increased expression of IRE1α associates with the resistant mechanism of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells[J]. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18(4), 550-555.
Authors:  Zheng-hai Tang;  Min-Xia Su;  Xia Guo;  Xiao-Ming Jiang;  Lin Jia; et al.
Favorite | TC[WOS]:0 TC[Scopus]:18 | Submit date：2018/12/28
Azd9291  Egfr  Ire1α  Lune Cancer  Nsclc  Osimertinib  
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies Journal article
Tang, Zheng-Hai, Lu, Jin-Jian. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies[J]. CANCER LETTERS, 2018, 420, 242-246.
Authors:  Tang, Zheng-Hai;  Lu, Jin-Jian
Favorite | TC[WOS]:100 TC[Scopus]:109  IF:9.1/8.3 | Submit date：2018/10/30
Osimertinib  Azd9291  Egfr Tki  Resistant Mechanisms  Therapeutic Strategies  
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells Journal article
Jiang, Xiao-Ming, Xu, Yu-Lian, Huang, Mu-Yang, Zhang, Le-Le, Su, Min-Xia, Chen, Xiuping, Lu, Jin-Jian. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells[J]. ACTA PHARMACOLOGICA SINICA, 2017, 38(11), 1512-1520.
Authors:  Jiang, Xiao-Ming;  Xu, Yu-Lian;  Huang, Mu-Yang;  Zhang, Le-Le;  Su, Min-Xia; et al.
Favorite | TC[WOS]:58 TC[Scopus]:60  IF:6.9/7.6 | Submit date：2018/10/30
Non-small Cell Lung Cancer  Egfr  Osimertinib  Pd-l1  Ubiquitin-proteasome System  Mg-132  Bortezomib  Gsk3 Beta  Licl  
Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells Journal article
Tang, Zheng-Hai, Cao, Wen-Xiang, Su, Min-Xia, Chen, Xiuping, Lu, Jin-Jian. Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells[J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 321, 18-26.
Authors:  Tang, Zheng-Hai;  Cao, Wen-Xiang;  Su, Min-Xia;  Chen, Xiuping;  Lu, Jin-Jian
Favorite | TC[WOS]:53 TC[Scopus]:54  IF:3.3/3.6 | Submit date：2018/10/30
Osimertinib  Azd9291  Autophagy  Apoptosis  Ros  
Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells Conference paper
Tang, ZH, Su, MX, Cao, WX, Chen, X. P., Lu, J.. Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells[C], 2016.
Authors:  Tang, ZH;  Su, MX;  Cao, WX;  Chen, X. P.;  Lu, J.
Favorite |  | Submit date：2022/08/26
Osimertinib  AZD9291  autophagy  apoptosis  NSCLC  
Treatment of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells by targeting inositol-requiring enzyme 1α Conference paper
Tang, ZH, Su, MX, Guo, XH, Jiang, XM, Chen, X. P., Lu, J.. Treatment of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells by targeting inositol-requiring enzyme 1α[C], 2016.
Authors:  Tang, ZH;  Su, MX;  Guo, XH;  Jiang, XM;  Chen, X. P.; et al.
Favorite |  | Submit date：2022/08/26
osimertinib  AZD9291  EGFR  IRE1α  NSCLC  
Characterization of osimertinib (AZD9291)-resistant non-small-cell lung cancer NCI-H1975/OSIR cell line Conference paper
Tang, ZH, Jiang, XM, Guo, X, Fong, CM, Wang, ZY, Chen, X. P., Lu, J.. Characterization of osimertinib (AZD9291)-resistant non-small-cell lung cancer NCI-H1975/OSIR cell line[C], 2016.
Authors:  Tang, ZH;  Jiang, XM;  Guo, X;  Fong, CM;  Wang, ZY; et al.
Favorite |  | Submit date：2022/08/26
osimertinib  resistance  EGFR  ABT-263